




REFERENCE MATERIAL ANALYSIS REPORT

Report ID: GP2U2.2015.01

Compound Name: **Ledipasvir**
Collection Number: GP2U_2
Chemical Formula: C₄₉H₅₄F₂N₈O₆
CAS Number: 1256388-51-8
Structure:

Description: White powder
Batch Number: 15-GP-02
Molecular Weight: 889.0
Release date: 7th October 2015



Synonyms: Methyl *N*-[(2*S*)-1-[(6*S*)-6-[5-[9,9-difluoro-7-[2-[(1*S*,2*S*,4*R*)-3-[(2*S*)-2-(methoxycarbonylamino)-3-methylbutanoyl]-3-azabicyclo[2.2.1]heptan-2-yl]-3*H*-benzimidazol-5-yl]fluoren-2-yl]-1*H*-imidazol-2-yl]-5-azaspiro[2.4]heptan-5-yl]-3-methyl-1-oxobutan-2-yl]carbamate
N-[(1*S*)-1-[(6*S*)-6-[5-[9,9-Difluoro-7-[2-[(1*R*,3*S*,4*S*)-2-[(2*S*)-2-[(methoxycarbonyl)amino]-3-methyl-1-oxobutyl]-2-azabicyclo[2.2.1]hept-3-yl]-1*H*-benzimidazol-6-yl]-9*H*-fluoren-2-yl]-1*H*-imidazol-2-yl]-5-azaspiro[2.4]hept-5-yl]carbonyl]-2-methylpropyl]-carbamic acid methyl ester

Purity (mass fraction): 92.7 ± 0.9% (95% coverage interval)

The purity value was obtained from a combination of traditional analytical techniques, by subtraction from 100% of total impurities by HPLC with UV detection, thermogravimetric analysis, Karl Fischer analysis, and ¹H NMR spectroscopy. Supporting evidence is provided by headspace GC-MS analysis of occluded solvent and elemental microanalysis.

HPLC: Instrument: Thermo Scientific Ultimate 3000 RS
Column: Alltima C-18, 5.0 µm (4.6 mm x 150 mm)
Column oven: 40 °C
Mobile Phase: A = Milli-Q water; B = MeOH; C = 2% formic acid in Milli-Q water.
Gradient: 0 min, 10% B, 10% C; 0-10 min, 10-65% B, 10% C; 10-25 min, 65% B, 10% C; 25-27 min, 65-90% B, 10% C; 27-30 min, 90% B, 10% C.
Flow rate: 1.0 mL/min
Detector: RS DAD operating at 328 nm
Relative peak area response of main component:
Initial analysis: Mean = 99.7%, s = 0.01% (10 sub samples in duplicate, September 2015)

Thermogravimetric analysis: Volatile content 5.4% and non volatile residue < 0.2% mass fraction (September 2015).

Karl Fischer analysis: Moisture content 0.3% mass fraction (August 2015)

Spectroscopic and other characterisation data

LC-MS:	<p>Instrument: Thermo Scientific Dionex UltiMate 3000 Degasser, Column: ZORBAX RRHD SB-C8, 2.1 x 50 mm, 1.8 µm (Agilent, 857700-906) Column temp: 30.0 °C Solvent system: Mobile phase A: 10 mM ammonium formate, 0.01% (v/v) formic acid in Milli-Q® water. Mobile phase B: 0.01% (v/v) formic acid in acetonitrile. Gradient from 90% A to 100% B</p> <p>Flow rate: 0.25 mL/min Sample prep: 2 mg/mL in MeOH with trace of formic acid Injection volume: 10 µL</p> <p>Ionisation mode: Electrospray positive ion Capillary voltage: 4.5 kV Capillary temp: 360°C Cone gas flow rate: 10 (arbitrary unit)</p> <p style="text-align: right;">Desolvation gas temperature: 300 °C Desolvation gas flow rate: 70 (arbitrary unit)</p> <p>The retention time of ledipasvir is reported along with the major peak in the mass spectrum. The latter is reported as a mass/charge ratio.</p> <p>11.71 min: 889.42314 (M+H⁺) m/z</p>
HS-GC-MS:	<p>Instrument: Agilent 6890/5973/G1888 Column: DB-624, 30 m x 0.25 mm I.D. x 1.4 µm Program: 50 °C (5 min), 7 °C/min to 120 °C, 15 °C/min to 220 °C (8.3 min) Injector: 150 °C Carrier: Helium, 1.2 mL/min Solvents detected: Acetone and ethyl acetate</p> <p style="text-align: right;">Transfer line temp: 280 °C Split ratio: 50/1</p>
TLC:	<p>Conditions: Kieselgel 60F₂₅₄. Ethyl acetate : methanol (95:5) Single spot observed, R_f = 0.33. Visualisation with UV at 254 nm</p>
IR:	<p>Instrument: Bruker Alpha FT-IR Range: 4000-400 cm⁻¹, neat Peaks: 1699, 1620, 1453, 1267, 1211, 1103, 1093, 1052, 1033, 940 cm⁻¹</p>
¹ H NMR:	<p>Instrument: Bruker Avance III 500 Field strength: 500 MHz Solvent: DMSO-<i>d</i>₆ (2.50 ppm)</p> <p>Spectral data: δ 0.51-0.63 (3H, m), 0.70 (1H, quintet, <i>J</i> = 3.7 Hz), 0.87 (6H, t, <i>J</i> = 6.1 Hz), 0.93 (3H, d, <i>J</i> = 6.8 Hz), 0.97 (3H, dd, <i>J</i> = 6.6 Hz), 1.46 (1H, d, <i>J</i> = 9.5 Hz), 1.54 (1H, m), 1.72-1.81 (2H, m), 1.89-2.06 (4H, m), 2.20 (1H, m), 2.40 (1H, d, <i>J</i> = 8.7 Hz), 2.65 (1H, s), 3.54 (3H, s), 3.55 (3H, s), 3.71 (1H, d, <i>J</i> = 9.7 Hz), 3.82 (1H, d, <i>J</i> = 9.8 Hz), 4.00 (1H, t, <i>J</i> = 8.4 Hz), 4.16 (1H, t, <i>J</i> = 8.0 Hz), 4.55 (1H, s), 4.66 (1H, d, <i>J</i> = 7.8 Hz), 5.20 (1H, dd, <i>J</i> = 5.2, 8.0 Hz), 7.23 (1H, d, <i>J</i> = 8.7 Hz), 7.33 (1H, d, <i>J</i> = 8.5 Hz), 7.50-7.62 (2H, m), 7.70-8.07 (9H, m), 11.87 (1H, s), 12.21 (1H, d, <i>J</i> = 6.1 Hz) ppm</p> <p>Acetone and ethyl acetate estimated at 6.1 and 0.3% mass fraction respectively were observed in the ¹H NMR.</p> <p>The ¹H NMR matches that for a sample of ledipasvir extracted from tablets of Twinvir™.</p>
Microanalysis:	<p>Found: C = 66.1%; H = 6.4%; N = 12.0%; F = 4.0% (August 2015) Calc: C = 66.0%; H = 6.4%; N = 11.8%; F = 4.0% (Calculated for C₄₉H₅₄F₂N₈O₆·C₃H₆O)</p>

Expiration of certification

The long-term stability of the compound in both solid form and in solution has not been examined. This material is extremely unstable in chloroform.

Homogeneity assessment

The homogeneity of the material was assessed using purity assay by HPLC with UV detection on ten randomly selected 1-2 mg sub samples of the material. The material was judged to be sufficiently homogeneous at this level of sampling as the variation in analysis results between samples was not significantly different at a 95% confidence level from that observed on repeat analysis of the same sample.

Metrological Traceability

The certified purity value is traceable to the SI unit for mass (kg) through Australian national standards via balance calibration. The purity was derived by subtraction of the mass of impurities from the mass of the reference material. Organic purity is traceable to the SI-derived coherent unit one through chromatographic separation and response factor determination of individual components. Volatile and non-volatile residue content is directly traceable to mass through use of Karl Fischer and thermogravimetric analysis.

Recommended storage

When not in use, this material should be stored at or below 4 °C in a closed container in a dry, dark area.

Intended Use

For *in vitro* laboratory analysis only.

Caution

Treat as hazardous substance. Use appropriate work practices when handling to avoid skin or eye contact, ingestion or inhalation of dust.

Legal notice

Neither NMI nor any person acting on NMI's behalf assumes any liability with respect to the use of, or for damages resulting from the use of, this reference material or the information contained in this certificate.

Authorised by:

S. R. Davies

Dr Stephen R. Davies,
Team Leader,
Chemical Reference Materials, NMI.
Dated: 7 October, 2015.